Limitations of our study are the facts that it was conducted retrospectively, that we did not have thrombocyte counts of all our patients, that about 25% of our patients with thrombocytosis were lost to follow-up and that we did not perform genetic testing in our whole database, so we do not have information on the presence of, e.g., a JAK2-mutation in ACS-patients without thrombocytosis. Here, JAK2 is linked to thrombocytosis disease.